The latest study from the Norwegian Drug Monitoring (NORDRUM) trial  shows that proactive therapeutic drug monitoring (TDM) for patients receiving maintenance infliximab therapy improves disease control, compared to treatment without TDM.
Therapeutic drug monitoring with infliximab improves disease control
Biosimilars/Research | Posted 15/07/2022 0 Post your comment
Therapeutic drug monitoring (TDM) aims to prevent treatment failures, following an initial response to treatment. There are two major types of TDM. Reactive TDM measures serum drug levels and the presence of anti-drug antibodies (ADAs) in response to evidence of disease, while proactive TDM regularly assesses these parameters in order to better optimize drug concentrations.
The latest study from the NORDRUM trial assessed the efficacy of proactive TDM in patients with inflammatory disease receiving maintenance infliximab treatment. Infliximab is a monoclonal antibody treatment that targets the inflammatory molecule tumour necrosis factor-alpha (TNF-α).
The randomized, parallel-group, open-label clinical trial involved 458 adults with a range of inflammatory conditions including rheumatoid arthritis, inflammatory bowel disease (IBD), and psoriasis.
Patients were randomized to receive proactive TDM, with regular monitoring of serum drug levels and ADAs and consequent dose and interval adjustments, or standard infliximab treatment without drug or ADA level monitoring. The study lasted for one year.
The study found that sustained disease control without disease worsening was achieved in 74% of patients in the TDM group, compared to 56% in the standard treatment group. Rates for discontinuing infliximab and adverse events were similar in both groups.
The authors conclude that, in patients with immune-mediated inflammatory diseases undergoing maintenance therapy with infliximab, proactive TDM is more effective in improving disease control.
However, they say more research is needed to compare proactive TDM to reactive TDM, to look at the effects on long-term complications, and to assess the cost-effectiveness of proactive TDM.
Co-author Dr Nils Bolstad, Senior Consultant and attending physician at Oslo University Hospital, said: ‘We recommend proactive TDM at least for infliximab in maintenance phase. We’re not sure if it’s a beneficial approach for other drugs. It should be tested in proper trials before making it standard of care’.
Proactive TDM is already used in Norway for IBD and some rheumatological and dermatological conditions, however, only the Australian Inflammatory Bowel Diseases Consensus Working Group and the US gastroenterology research group BRIDGe officially recommend proactive TDM.
Submit a manuscript to GaBI Journal
LATIN AMERICAN FORUM
The new section of the ‘Latin American Forum’ on GaBI has been launched. The objective of this new section is to provide you with all the latest news and updates on developments of generic and biosimilar medicines in Latin America in Spanish.
View last week’s headline article: Directrices revisadas de la OMS para los biosimilares: antecedentes científicos
Browse the news in the Latin American Forum!
LATIN AMERICAN FORUM
Se ha lanzado la nueva sección del ‘Foro Latinoamericano’ sobre GaBI. El objetivo de esta nueva sección es brindarle las últimas noticias y actualizaciones sobre desarrollos de medicamentos genéricos y biosimilares en América Latina en español.
Vea el artículo principal de la semana pasada: Directrices revisadas de la OMS para los biosimilares: antecedentes científicos
!Explore las noticias en el Foro Latinoamericano!
1. Syversen SW, Jørgensen KK, Goll GL, et al. Effect of therapeutic drug monitoring vs standard therapy during maintenance infliximab therapy on disease control in patients with immune-mediated inflammatory diseases: a randomized clinical trial. JAMA. 2021;326(23):2375-84. doi:10.1001/jama.2021.21316
Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.
Copyright – Unless otherwise stated all contents of this website are © 2022 Pro Pharma Communications International. All Rights Reserved.